Last reviewed · How we verify
Seasonal Inactivated Influenza Vaccine
Seasonal Inactivated Influenza Vaccine is a Inactivated vaccine Biologic drug developed by Pfizer. It is currently FDA-approved for Prevention of seasonal influenza in adults and children ≥6 months of age. Also known as: SIIV, FluZone.
The vaccine stimulates the immune system to produce antibodies and cellular immunity against seasonal influenza virus strains.
The vaccine stimulates the immune system to produce antibodies and cellular immunity against seasonal influenza virus strains. Used for Prevention of seasonal influenza in adults and children ≥6 months of age.
At a glance
| Generic name | Seasonal Inactivated Influenza Vaccine |
|---|---|
| Also known as | SIIV, FluZone |
| Sponsor | Pfizer |
| Drug class | Inactivated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Seasonal inactivated influenza vaccine contains inactivated (killed) influenza virus particles or viral antigens that trigger both humoral (antibody) and cell-mediated immune responses. Upon vaccination, the immune system recognizes these antigens and develops protective immunity, enabling faster and more effective recognition and neutralization of circulating influenza viruses if exposure occurs.
Approved indications
- Prevention of seasonal influenza in adults and children ≥6 months of age
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- COVID-19 Booster and IIV Schedule in Immunocompromised Hosts (PHASE2)
- Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (PHASE1)
- Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults (PHASE4)
- Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older (PHASE3)
- Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Seasonal Inactivated Influenza Vaccine CI brief — competitive landscape report
- Seasonal Inactivated Influenza Vaccine updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Seasonal Inactivated Influenza Vaccine
What is Seasonal Inactivated Influenza Vaccine?
How does Seasonal Inactivated Influenza Vaccine work?
What is Seasonal Inactivated Influenza Vaccine used for?
Who makes Seasonal Inactivated Influenza Vaccine?
Is Seasonal Inactivated Influenza Vaccine also known as anything else?
What drug class is Seasonal Inactivated Influenza Vaccine in?
What development phase is Seasonal Inactivated Influenza Vaccine in?
What are the side effects of Seasonal Inactivated Influenza Vaccine?
Related
- Drug class: All Inactivated vaccine drugs
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of seasonal influenza in adults and children ≥6 months of age
- Also known as: SIIV, FluZone
- Compare: Seasonal Inactivated Influenza Vaccine vs similar drugs
- Pricing: Seasonal Inactivated Influenza Vaccine cost, discount & access